Table 2.
Summary of the primary treatment costs applied in the economic models
| Units | Total costs* | Source | |
|---|---|---|---|
| TIPSS procedure | |||
| Indication 1 (AVB) | |||
| Elective | 0.05 | €5851.99 | KOLs; [18, 30, 31] |
| Non-elective | 0.95 | €7615.99 | |
| Total | €7527.79 | ||
| Indication 2 (RA) | |||
| Elective | 1.00 | €5851.99 | KOLs; [18, 30, 31] |
| Non-elective | 0.00 | €7615.99 | |
| Total | €5851.99 | ||
| Standard care: indication 1 (AVB) | |||
| Outpatient EBL (months 1–2) | 4.00 | €4689.30 | KOLs; [32, 33] |
| Outpatient EBL (months 3–24) | 3.00 | ||
| Pharmaceuticals (per month) | Various** | €7.79 | KOLs; [33] |
| Total costs (24-month survival)*** | €4750.80 | ||
| Standard care: indication 2 (RA) | |||
| LVP per procedure | 2.17 | €2430.49 | KOLs; [18, 30, 33] |
| Total cost (24-month survival)*** | €58,331.68 | ||
KOL key opinion leaders
*See supplementary material for breakdown of AE costs
**Carvedilol (25% of population applied to) and propranolol (75% of population applied to)
***Undiscounted total 24-month cost estimates